The product information summary sits at the core of the creation guide. It is the foundational material for delivering accurate information about an individual prescription drug to healthcare professionals and for advancing appropriate use. Within the guide's three-part structure (Part I product information summaries, Part II advertisements in professional print journals, Part III other materials), it is also the prototype that the other two parts lean on. The advertising rules in Part II are this part's craft compressed into narrow space, and the materials in Part III are told to "fall back on the spirit of the product information summary when no specific rule exists" precisely because this part serves as the reference point for every other judgment.
This entry page is a map of how to descend: Chapter 1 (basic points of attention) to Chapter 2 (the 16 items of the comprehensive summary) to Chapter 3 (the specific-item summary). Grasp the underlying reasoning first, then move down to the individual rules; the "why" behind each rule becomes far easier to see.
01Why the "summary" is the core
The foreword states plainly that the basis of appropriate-use information is the electronic package insert, and that product information summaries and the like complement it. That single word, "complement," fixes the standing of the summary. The original is the approved content; the summary ranks below it. So the summary cannot exceed the scope of approval by even one character. It is a core material that nonetheless never becomes the source text itself — this duality is the first key to reading product information summaries.
Then why is a summary needed at all, on top of the package insert? The insert lays out the legally required items without excess or omission; it is not the place to narrate the development history, the full picture of trial design, or the chain of pharmacological action. Under the constraint of never straying from the fact of approval, the summary re-weaves that background and evidence into a form healthcare professionals can verify. It helps to think of it not as a material that adds facts, but one that arranges the path to those facts.
02Two forms — comprehensive and specific-item
Product information summaries come in two forms: the comprehensive product information summary, which covers the whole picture of the product, and the specific-item product information summary, which narrows to particular items such as the explanation of features, pharmacological action, clinical results, indications, or dosage. The basic points of attention in Chapter 1 apply equally to both forms. Even the specific-item version must follow the Chapter 2 rules that correspond to the items it covers. Narrowing the form does not dilute the principles that must be upheld — that is how it is designed.
| Aspect | Comprehensive summary | Specific-item summary |
|---|---|---|
| Scope | Covers the whole picture of the product | Limited to specific items: features, pharmacology, clinical results, indications, dosage |
| Chapters followed | Chapter 1 + Chapter 2 (all 16 items) | Chapter 1 + applicable Chapter 2 items + Chapter 3 |
| Shared constraints | No exceeding the scope of approval / balance of efficacy and safety / verifiability secured | |
The split into two forms is a practical allowance: you may build the material to match the breadth of points you want to convey. But so that "narrowing" does not quietly turn into "dropping the inconvenient parts," Chapter 3 sets out required items for the specific-item version in fine detail.
03The three-chapter structure — foundation, fixed form, limited form
Part I is built from three chapters, each with a different character.
Chapter 1 — Basic points of attention: the foundation that applies to all materials
The handling of scientific evidence, the balance of efficacy and safety, adherence to the scope of approval, isolation of reference information, the ban on exaggeration and misunderstanding, the ban on disparagement, and consistency and updating. Roughly 20 points of attention, plus the handling of figures and tables (data), gather here. Not only product information summaries but every material the guide covers takes this chapter as its starting point. Skip Chapter 1 and jump to individual items, and you easily lose sight of the "why" behind each rule.
Chapter 2 — Comprehensive summary: the fixed form of 16 items
It fixes the items to be recorded at 16, and regulates even their order. It leaves the writer no room to pick and choose, requiring complete recording along a set template. This is also a device against turning the guide into an "answer key." Leave what to include to the writer's discretion, and only the convenient items survive. By fixing even the order, the guide closes that escape route.
Chapter 3 — Specific-item summary: the core you cannot drop even when narrowing
It is a summary narrowed to particular items, yet required items are set out in detail: classification number, name, warnings/contraindications, indications, dosage, adverse reactions, and the date of preparation or revision. On top of complying with Chapters 1 and 2, additional rules unique to the limited version stack up (the post-marketing surveillance mark, the cross-reference to the package insert when consolidating into the DI section, the minimum font size, and so on).
04How the foreword's spirit descends into this part
The foreword serves as the constitution of the whole guide, and its implications are made concrete in the rules of the product information summary. Three pillars in particular run through the detailed provisions of Part I.
Closing off "true but misleading"
The duty not to lie and the duty not to mislead are different things. Even when the data themselves are correct, if the way they are shown forms a mistaken impression, it is a violation. That is exactly why there are restraints on figures and tables: show actual counts rather than graphs or percentages when case numbers are small, do not state a risk reduction rate when there is no significant difference, do not use arrows to emphasize the gap against a comparator. These rules implement "do not mislead," not merely "do not lie."
Implementing balance through structure
If you write efficacy, you write safety with the same weight. The font size for safety is the same as, or larger than, the body text for efficacy. Reference information does not exceed a set proportion of the page. These are not a mindset of "please be mindful of balance" but structural constraints translated into measurable quantities — font size and area. Rather than relying on the reader's conscience, the physical quantity of the page guarantees the balance.
Safety information is disclosed even when it is unfavorable — this is a duty asymmetric with efficacy information. The seller has no freedom to bury findings that are inconvenient to them. The provisions scattered through Part I requiring that any pharmacological or toxicological finding capable of causing adverse reactions in the clinic must always be recorded stem from this asymmetry.
Securing verifiability through structure
Sources, statistical methods, and the date of preparation or revision. By requiring these to always be left in place, the guide keeps the claims in a state where a third party can retrace them later. It is no accident that the last of the 16 items is "date of preparation or revision." Not a flashy prohibition, but the accumulation of the plain discipline of leaving a version behind and enabling verification and recall is what supports a material's trustworthiness.
05Connection to the discipline of science
Much of what a product information summary handles is the results of clinical trials. So the guide's rules are continuous with the discipline of evidence and statistics. Grasp this, and the individual prohibitions reveal themselves not as a mere list of rules but as a translation of the craft of science.
The evidence hierarchy and pre-specification
Meta-analyses and systematic reviews, randomized controlled trials, observational studies, case reports, expert opinion — there is a hierarchy in the strength of evidence. The presence or absence of peer review is the watershed of quality. In vitro and animal results are not connected directly to the clinic, because of differences in species, dose, and system. The guide's requirement to mark animal data with "(animal species)" and in vitro data with "(in vitro)," and not to let them be used as a guarantee of clinical effect, carries this hierarchy into the material's notation.
A significant difference is not clinical significance
A p-value merely expresses the probability of obtaining a difference this large or larger by chance, assuming there is no difference; it says nothing about the magnitude of effect or its clinical value. In a large trial even a tiny difference becomes significant, and conversely the absence of a significant difference does not mean equivalence. A result confirmed in a confirmatory manner on a single, pre-specified primary endpoint carries a completely different weight for conclusions than a nominal p-value pulled out after the fact. The summary's repeated demand to "make clear whether a result is confirmatory or a nominal p-value" exists to keep readers from confusing the two.
Same data, different impression. From the identical trial result, slice out only a subgroup, emphasize the gap with arrows, and compute a risk reduction rate from a non-significant hazard ratio — and an image more effective than reality rises up. The guide's rules on figures and tables close this "room for impression management" one by one. The facts are unchanged, yet a misunderstanding is born — sealing that gap is the role of Section 2 of Chapter 1.
06How to walk through this part
The summary's rules are many in number and, at first glance, look like a litany of prohibitions. But follow the order and the logic holds. First grasp the "why" in Chapter 1: take in the underlying ideas of balance, scope of approval, the ban on misunderstanding, and verifiability before anything else. Next read the 16 items of Chapter 2 in their flow — from the development history to features and clinical results (the core of efficacy), through handling and the like, always closing with the main references (the basis) and the date of preparation or revision (the version). Finally, in Chapter 3, check the additional rules unique to the narrowed version.
Looking at the related norms alongside this stabilizes the positioning. The guide is a practical manual that translates the principles of the Fair Advertising Standards and the JPMA Code into "how to build the material," and areas outside its provisions remain governed by these higher norms. What is not in the manual does not mean freedom — the foreword's implication holds here too.
The product information summary is the core material that complements the package insert, the original text. Under the constraint of never straying from the fact of approval, it re-weaves the background and evidence into a verifiable form. It is core, yet never the source — keep this standing in mind, and the "why" of each rule comes into view.
The three chapters shift in character — foundation (Chapter 1), fixed form (Chapter 2), limited form (Chapter 3) — while giving concrete shape to the foreword's three pillars: closing off misunderstanding, implementing balance through structure, and securing verifiability. Next, descend into Chapter 1 and read on from the basic points of attention that apply to every material.